ReviewJournal of the Society for Cardiovascular Angiography & Interventions2025
A Blueprint for Building a Renal Denervation Program.
Review in Journal of the Society for Cardiovascular Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal denervation (RDN) has emerged as a promising adjunctive therapy for hypertension, particularly in patients with poor blood pressure control despite pharmacologic and lifestyle interventions. With the recent approval of 2 RDN systems by the US Food and Drug Administration, there is growing opportunity for interested interventional cardiologists to develop expertise in this rapidly evolving, unsaturated field. This review serves as a comprehensive guide to building an RDN program, covering team development, training requirements, workflow design, and economic considerations. Interventional cardiologists, particularly fellows-in-training and those at early career stages, are uniquely positioned to advance this emerging technology by leveraging their multidisciplinary training, technological fluency, and openness to innovation to shape the future of interventional hypertension care. This blueprint offers a practical roadmap to capitalize on the clinical and career opportunities that RDN presents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.